Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 6/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.49 |
| ▸ | PRKG1 | Q13976 | 3/20 | 0.49 |
| ▸ | PRKACA | P17612 | 3/20 | 0.49 |
| ▸ | GSK3A | P49840 | 3/20 | 0.49 |
| ▸ | GSK3B | P49841 | 3/20 | 0.49 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.49 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.49 |
| ▸ | PRKCG | P05129 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 2/20 | 0.49 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.49 |
| ▸ | CDK2 | P24941 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | AKT2 | P31751 | 2/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.49 |
| ▸ | PRKX | P51817 | 2/20 | 0.49 |
| ▸ | NEK4 | P51957 | 2/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.49 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.49 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7142373 | 0.79 | NPC1 (0.54) | ROCK1ROCK2PRKG1PRKACAGSK3A | |
| Hydrochloric Acid SCHEMBL11490909 | 0.79 | CES2 (0.51) | ROCK1ROCK2PRKG1PRKACAGSK3A | |
| Bromide SCHEMBL6283052 | 0.78 | NPC1 (0.53) | ROCK1ROCK2PRKG1PRKACAGSK3A | |
| Hydrochloric Acid SCHEMBL6708543 | 0.78 | NPC1 (0.53) | ROCK1ROCK2PRKG1PRKACAGSK3A | |
| SCHEMBL6707539 | 0.76 | ALDH1A1 (0.48) | ROCK1ROCK2PRKG1PRKACAGSK3A | |
| SCHEMBL1398796 | 0.75 | CES2 (0.53) | KMT2AALDH1A1NPC1CES2CES1 | |
| SCHEMBL6707538 | 0.73 | LTA4H (0.47) | ROCK2CYP3A4KMT2AALDH1A1NPC1 | |
| SCHEMBL7048516 | 0.73 | CTSS (0.54) | MAPK1KMT2AALDH1A1NPC1CES2 | |
| SCHEMBL4029309 | 0.72 | CES2 (0.77) | MAPK1CYP2D6CYP3A4CYP2C9KMT2A | |
| SCHEMBL5216406 | 0.72 | KMT2A (0.72) | CDK5CYP2D6KMT2AALDH1A1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106793-A1 | Oxazoles for treating cytokine mediated diseases | SMITHKLINE BEECHAM CORPORATION | 2004-06-03 | — | — | US | disclosed |
| EP-0727998-B1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 2004-01-21 | — | — | EP | disclosed |
| EP-1306377-A2 | Pyridyl-oxazoles and their use as cytokines inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2003-05-02 | — | — | EP | disclosed |
| US-20020169173-A1 | Oxazoles for treating cytokine mediated diseases | SMITHKLINE BEECHAM CORPORATION | 2002-11-14 | — | — | US | disclosed |
| US-6288062-B1 | INTERLEUKIN AND TUMOR NECROSIS FACTOR INHIBITORS; ANTIINFLAMMATORY AGENTS; RHEUMATIC DISEASES; ANTIARTHRITIC AGENTS; RESPIRATORY SYSTEM DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2001-09-11 | — | — | US | disclosed |
| EP-0727998-A4 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORP (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0727998-A1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1996-08-28 | — | — | EP | disclosed |
| WO-1995013067-A1 | OXAZOLES FOR TREATING CYTOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106793-A1 | Oxazoles for treating cytokine mediated diseases | IL2, IL17A, IL5 | ROCK1 2672/4885ROCK2 3627/4885PRKG1 3233/4885 |
| US-20020169173-A1 | Oxazoles for treating cytokine mediated diseases | IL17A, IL4I1, IL2 | ROCK1 3366/4885ROCK2 4326/4885PRKG1 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.